Amgen today announced a $1bn expansion to establish a second drug substance manufacturing facility in North Carolina. This brings the company’s total planned investment in Holly Springs to more than $1.5 billion, building on its previously announced $550 million commitment.
“This expansion underscores our unwavering focus on bringing transformative medicines to patients around the world,” said Robert A. Bradway, chairman and chief executive officer at Amgen. “North Carolina will be an important part of our global manufacturing network as we continue to meet the growing demand for our innovative therapies while generating significant local economic impact.”
“North Carolina’s reputation as one of the world’s leading centers for biotechnology soars even higher with today’s decision by Amgen,” said North Carolina Governor Roy Cooper. “North Carolina offers everything an innovative biotech company needs to succeed, especially our highly trained, dedicated and diverse workforce which is fine-tuned to the needs of this critical industry.”
The $1 billion facility will incorporate cutting-edge technologies and sustainable practices, aligning with Amgen’s commitment to environmental stewardship and manufacturing excellence. In tandem with the existing facility, these investments will create 370 new jobs in the region, supporting a robust biomanufacturing hub.
Amgen’s choice of North Carolina reflects its position as a premier life sciences destination, with a vibrant ecosystem of innovation and a skilled workforce. This expansion enhances the company’s global biomanufacturing network, leveraging decades of operational expertise and technological advancements to ensure the reliable and efficient delivery of high-quality medicines to patients worldwide.
